PRVB News and Press, Provention Bio Inc. From 03/23/20

Pharmaceutical giant Eli Lilly (NYSE: LLY) has been doing its part in the battle against COVID-19. It teamed up with the Indiana State Department of Health to make more testing for the disease available to people in its home state, and plans to start offering drive-thru testing for COVID...

Drug companies have run into another serious problem stemming from the COVID-19 outbreak -- the pandemic is making it harder to run clinical trials for all types of treatments. The Food and Drug Administration requires multiple successful clinical trials before a new drug can be sold to the publ...

The COVID-19 pandemic is having a profound impact on the lives and day to day activities of millions of people in the United States. Many states have decided to take drastic measures to mitigate the spread of the potentially deadly disease, such as closing public schools, bars, and gyms, and ban...

Citing the need for caution during the COVID-19 outbreak, Provention Bio (NASDAQ: PRVB ) has suspended recruitment in its Phase 3 PROTECT study evaluating teplizumab (PRV-031) in newly diagnosed type 1 diabetics. More news on: Provention Bio, Inc., Healthcare stocks news, Read more...

OLDWICK, N.J. , March 16, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced a temporary pause in the randomization of patients with newly diagnosed type 1 ...

Provention Bio, Inc. (PRVB) Q4 2019 Earnings Conference Call March 12, 2020, 08:30 AM ET Company Participants Sam Martin - Investor Relations Andrew Drechsler - Chief Financial Officer Ashleigh Palmer - Co-Founder and Chief Executive Officer Francisco Leon - Co-Founder and Chie...

Image source: The Motley Fool. Provention Bio, Inc   (NASDAQ: PRVB) Q4 2019 Earnings Call Mar 12, 2020 , 8:30 a.m. ET Operator Continue reading

OLDWICK, N.J. , March 12, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December ...

OLDWICK, N.J. , March 12, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced positive top-line results from the Phase 1b portion of the PREVAIL (PRV-3279 ...

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...